Daily1d
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
FiercePharma3d
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
PMLiVE1d
AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
PharmiWeb6d
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...
BioSpace10h
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
FiercePharma4d
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Bernstein Sticks to Their Buy Rating for Astellas Pharma (ALPMF)
In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
Hosted on MSN6d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
AstraZeneca gets first US approval for cancer treatment Datroway
AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi ...
BioPharma Dive9h
What will 2025 hold for biopharma?
Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...